BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 21085470)

  • 1. Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.
    Nico D; Claser C; Borja-Cabrera GP; Travassos LR; Palatnik M; Soares IS; Rodrigues MM; Palatnik-de-Sousa CB
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e866. PubMed ID: 21085470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal Domains.
    Nico D; Gomes DC; Alves-Silva MV; Freitas EO; Morrot A; Bahia D; Palatnik M; Rodrigues MM; Palatnik-de-Sousa CB
    Front Immunol; 2014; 5():189. PubMed ID: 24822054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The F1F3 Recombinant Chimera of
    Alves-Silva MV; Nico D; de Luca PM; Palatnik de-Sousa CB
    Front Immunol; 2019; 10():724. PubMed ID: 31024556
    [No Abstract]   [Full Text] [Related]  

  • 4. NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.
    Nico D; Martins Almeida F; Maria Motta J; Soares Dos Santos Cardoso F; Freire-de-Lima CG; Freire-de-Lima L; de Luca PM; Maria Blanco Martinez A; Morrot A; Palatnik-de-Sousa CB
    Front Immunol; 2018; 9():967. PubMed ID: 29867949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoside Hydrolase NH 36: A Vital Enzyme for the
    Palatnik-de-Sousa CB
    Front Immunol; 2019; 10():813. PubMed ID: 31040850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the
    Alves-Silva MV; Nico D; Morrot A; Palatnik M; Palatnik-de-Sousa CB
    Front Immunol; 2017; 8():100. PubMed ID: 28280494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine Infection.
    Nico D; Gomes DC; Palatnik-de-Sousa I; Morrot A; Palatnik M; Palatnik-de-Sousa CB
    Front Immunol; 2014; 5():273. PubMed ID: 24966857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach.
    Kashyap M; Jaiswal V; Farooq U
    Infect Genet Evol; 2017 Sep; 53():107-115. PubMed ID: 28549876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.
    Aguilar-Be I; da Silva Zardo R; Paraguai de Souza E; Borja-Cabrera GP; Rosado-Vallado M; Mut-Martin M; García-Miss Mdel R; Palatnik de Sousa CB; Dumonteil E
    Infect Immun; 2005 Feb; 73(2):812-9. PubMed ID: 15664920
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Barbosa Santos ML; Nico D; de Oliveira FA; Barreto AS; Palatnik-de-Sousa I; Carrillo E; Moreno J; de Luca PM; Morrot A; Rosa DS; Palatnik M; Bani-Corrêa C; de Almeida RP; Palatnik-de-Sousa CB
    Front Immunol; 2017; 8():227. PubMed ID: 28321221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania infantum amastin protein incorporated in distinct adjuvant systems induces protection against visceral leishmaniasis.
    Ribeiro PAF; Vale DL; Dias DS; Lage DP; Mendonça DVC; Ramos FF; Carvalho LM; Carvalho AMRS; Steiner BT; Roque MC; Oliveira-da-Silva JA; Oliveira JS; Tavares GSV; Galvani NC; Martins VT; Chávez-Fumagalli MA; Roatt BM; Moreira RLF; Menezes-Souza D; Oliveira MC; Machado-de-Ávila RA; Teixeira AL; Coelho EAF
    Cytokine; 2020 May; 129():155031. PubMed ID: 32062145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous priming-boosting with DNA and vaccinia virus expressing kinetoplastid membrane protein-11 induces potent cellular immune response and confers protection against infection with antimony resistant and sensitive strains of Leishmania (Leishmania) donovani.
    Guha R; Das S; Ghosh J; Naskar K; Mandala A; Sundar S; Dujardin JC; Roy S
    Vaccine; 2013 Apr; 31(15):1905-15. PubMed ID: 23499564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IFN-γ
    Yadav S; Prakash J; Singh OP; Gedda MR; Chauhan SB; Sundar S; Dubey VK
    Cell Immunol; 2021 Mar; 361():104272. PubMed ID: 33445051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-gamma and cytolytic activity by CD8+ T cells.
    Resende DM; Caetano BC; Dutra MS; Penido ML; Abrantes CF; Verly RM; Resende JM; Piló-Veloso D; Rezende SA; Bruna-Romero O; Fernandes AP; Gazzinelli RT
    Vaccine; 2008 Aug; 26(35):4585-93. PubMed ID: 18588933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with a CD4
    Dias DS; Ribeiro PAF; Martins VT; Lage DP; Costa LE; Chávez-Fumagalli MA; Ramos FF; Santos TTO; Ludolf F; Oliveira JS; Mendes TAO; Silva ES; Galdino AS; Duarte MC; Roatt BM; Menezes-Souza D; Teixeira AL; Coelho EAF
    Transl Res; 2018 Oct; 200():18-34. PubMed ID: 29908151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.
    Bhattacharya P; Dey R; Dagur PK; Joshi AB; Ismail N; Gannavaram S; Debrabant A; Akue AD; KuKuruga MA; Selvapandiyan A; McCoy JP; Nakhasi HL
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004963. PubMed ID: 27580076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.